Company: XAIR
Filing Date: 2025-06-20
Form Type: 10-K
Source: 0001641172-25-015750
Chunk: 815

Company: Beyond Air, Inc.
Filing Date: 2025-06-20
Form: 10-K
Item: Item 1A
Chunk 815
---
laws or Delaware law that has the effect of delaying
or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common
stock, and could also affect the price that some investors are willing to pay for our common stock.

The existence of the foregoing
provisions and anti-takeover measures could limit the price that investors might be willing to pay in the future for shares of our common
stock. They could also deter potential acquirers of the Company, thereby reducing the likelihood that you could receive a premium for
your common stock in an acquisition.

70

Risks Related to Employee Matters

Our business could suffer if we lose the services
of key members of our senior management, key advisors or personnel.

We are dependent upon the continued
services of key members of our senior management and a limited number of key advisors and personnel. The loss of any one of these individuals
could disrupt our operations or our strategic plans. Additionally, our future success will depend on, among other things, our ability
to continue to hire and retain the necessary qualified scientific, technical and managerial personnel, for whom we compete with numerous
other companies, academic institutions and organizations. The loss of members of our management team, key advisors or personnel, or our
inability to attract or retain other qualified personnel or advisors, could have a material adverse effect on our business, results of
operations and financial condition. Though members of our sales force generally enter into noncompetition agreements that restrict their
ability to compete with us, most of the members of our executive management team are not subject to such agreements. Accordingly, the
adverse effect resulting from the loss of certain executives could be compounded by our inability to prevent them from competing with
us.

Our employees may engage in misconduct or other
improper activities, including noncompliance with regulatory standards and requirements and insider trading.

We are exposed to the risk of employee fraud or other
misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, to provide accurate information
to the FDA, to comply with federal and state healthcare fraud and abuse laws and regulations, to report financial information or data
accurately, to disclose unauthorized activities to us or to comply with our code of business conduct and ethics. In particular, sales,
marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud,
kickbacks, false claims, inappropriate promotion, self-dealing and other abusive practices. These laws and regulations